Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History

Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History

Sanjay Sethi,1 Brendan Clark,2 Lindsay GS Bengtson,3 Erin K Buysman,3 Swetha Palli,2 Andrew Sargent,3 Asif Shaikh,2 Gary T Ferguson4 1Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; 2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 3Optum L...

Full description

Bibliographic Details
Main Authors: Sethi S, Clark B, Bengtson LG, Buysman EK, Palli S, Sargent A, Shaikh A, Ferguson GT
Format: Article
Language:English
Published: Dove Medical Press 2023-04-01
Series:International Journal of COPD
Subjects:
copd
tiotropium bromide/olodaterol
fluticasone furoate/umeclidinium/vilanterol
exacerbation history
healthcare resource utilization
cost
clinical outcomes
Online Access:https://www.dovepress.com/healthcare-resource-utilization-cost-and-clinical-outcomes-in-patients-peer-reviewed-fulltext-article-COPD

Internet

https://www.dovepress.com/healthcare-resource-utilization-cost-and-clinical-outcomes-in-patients-peer-reviewed-fulltext-article-COPD

Similar Items